Medications dispensed from the Saskatchewan Cancer Agency (SCA) will start appearing on PIP (Pharmaceutical Information Program) on August 29, 2022.

This addition will:

- Increase patient safety and improve treatment decisions with a more complete patient medication profile that includes cancer treatments.
 - Assist clinicians in assessing patients for:
 - oncology related toxicity
 - o adverse reactions or side-effects of treatment
 - o febrile neutropenia
 - o oncology related drug interactions
- Prompt oncology consults where appropriate.

Background:



ALERT: Medication dispensed by SCA on and after August 29, 2022 will appear in PIP. SCA medications filled prior Aug 29 will <u>never</u> display.

Medications will display in:

- eHealth's Pharmaceutical Information Program (PIP)
- the Preadmission Medication List / Prescriber Order Form (used for the Best Possible Medication History (BPMH) form, sometimes inaccurately referred to as the "PIP" form)
- Downstream applications such as MySask Health Record and eHealth eHR Viewer.



ALERT: Dose, route, interval, and directions are not transmitted. Continue to use other sources to verify this information (patient interview, call dispensing pharmacy, etc.).

PIP online or eHR Viewer will display the dispensing pharmacy as either from Allan Blair Cancer Centre (ABCC) or Saskatoon Cancer Centre (SCC). This includes doses administered at:

- Outpatients at SCA affiliated COPS (Community Oncology Program of Saskatchewan) centers
- Outpatient Treatment Centre (Regina) and Day Centre (Saskatoon)
- Outpatient Home Injection Programs
- Inpatients in SHA hospitals, including JPCH (Jim Pattison Children's Hospital)

Assessment:

- Prescriber and medication name are the only way to identify a medication is prescribed for cancer treatment on the Preadmission Medication List / Prescriber Order Form.
- IV (Intravenous) cancer treatment orders will only be ordered by an oncologist. SCA order sets will be used to order IV Cancer treatments to ensure all required information is available.




Impact to SHA Medication Reconciliation:

The MedRec process remains unchanged EXCEPT for IV cancer treatments.

• For IV cancer treatment medications, cross out dose and interval, but fill in date of last dose.

- For prescribers:
 - When discontinuing IV Cancer treatment, check off "stop" and leave comment indicating cancer treatment dose complete or other reason for stopping treatment.
 - If order is to continue check off "change" and leave comment referring to oncologist's order or asking for an oncology consult.
 - IV cancer treatment orders (chemotherapy, immunotherapy, targeted therapy) will NOT be accepted as orders on the Preadmission Medication List / Prescriber Order Form.



Continue to:

- ✓ Ask patients about active cancer treatments. All other medications, including SCA supportive care meds or post therapy medications, require dose and interval, as per usual process of gathering the BPMH.
- Indicate continuation of patient's own oral oncology medication on the PIP form with complete dose, interval, time/date of last dose and duration info.
- ✓ Assess to determine if cancer medication is contributing to a patient's need for admission.
- ✓ Consider an oncology consult, if required, before stopping or continuing any cancer therapy.
- ✓ Use SCA progress notes in eHR Viewer to find more information about a cancer treatment.

Follow –up action:

Healthcare providers with MedRec in their job assignment please watch a short 20 minute presentation about the SCA medication and PIP integration on the <u>Medication Reconciliation intranet page</u> (SHA intranet at Departments \rightarrow Clinical Standards \rightarrow Clinical Resources \rightarrow Pharmacy Resources \rightarrow Medication Reconciliation).

